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Abstract
Background: Respiratory secretions impact negatively on palliative patients. Unfortunately, a gold standard therapy
is not yet available. The purpose of this study was to identify which interventions are in use to control respiratory
secretions in patients with chronic disease with a poor prognosis and verify their effects on outcomes relevant for
palliative care patients.
Methods: A systematic review of the literature with narrative summary was conducted. We searched eight
electronic databases in April 6th, 2016. Citation-tracking and reference list searches were conducted. We included
randomized controlled trials, crossover trials, observational and qualitative studies regarding interventions for
respiratory secretion management in adult patients with chronic diseases that met inclusion criteria indicating short
prognosis.
Results: Six randomized controlled trials, 11 observational studies, ten crossover trials and one qualitative study
were found. Interventions included mechanical insufflation-exsufflation (MIE), expiratory muscle training, manually-
assisted cough, tracheotomy, chest physiotherapy, suctioning, air stacking, electrical stimulation of abdominal
muscles, nebulized saline, positive expiratory pressure masks, percussive ventilation, high frequency chest wall
oscillations. The interventions with most promising benefits to patients in palliative care were manually-assisted
cough and mechanical insufflation-exsufflation to promote expectoration and percussive ventilation to improve
mucous clearance.
Conclusion: Therapies, such as manually assisted cough, mechanical insufflation-exsufflation and percussive
ventilation, which aim to deal with respiratory secretion, were the most promising treatment for use in palliative care
for specific diseases. Nevertheless, the evidence still needs to improve in order to identify which treatment is the best.
Keywords: Respiratory secretion, Palliative Care, Cough, Sputum
Background
The presence of mucus within and around the respira-
tory tract towards the end-of-life can be burdensome,
for patients already facing death for a number of rea-
sons. Continuous accumulation of mucus tends to nega-
tively impact the quality of life and the dying process
and leads to social isolation as excessive expectoration
may be disturbing to some people and cultures [1].
However research around the benefits of interventions
used to manage this symptom is somewhat scarce. Prob-
lems in dealing with respiratory secretions are caused by
increased production of airway secretions or inefficient
elimination of the mucus or both and as a result, mucus
encumbrance is difficult to control.
The increased production of respiratory mucus is
common in patients with cardiorespiratory [2] diseases
and lung, head and neck cancer. Sometimes these condi-
tions are associated with cough inefficiency due to
muscle weakness and poor coordination [3, 4]. However,
other diseases may cause this discomfort only due to a
deficiency in mucus elimination caused by cough ineffi-
ciency such as in neurologic diseases [1, 5–7]. Most of
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the diseases associated with the presence of respiratory
secretion are chronic conditions and they may be life-
threatening in their later stages, which is an indication
for palliative care.
As a consequence to patients, an augmented amount
of secretion is associated with an increase in dyspnoea,
cough and the chances of respiratory complications,
such as pneumonia. Furthermore, there is an associated
poor prognosis in chronic obstructive pulmonary disease
(COPD) patients [3, 4] and secretions may interfere in
the efficacy of other interventions, such as non-invasive
ventilation. Unfortunately, a gold standard therapy is not
yet available.
The interventions to help patients deal with respira-
tory secretion have different goals and the choice must
depend on the patient’s condition. Three main goals are:
(1) promote expectoration; (2) increase mucociliary
clearance and conduct of the secretions to the upper air-
ways; (3) improve cough effectiveness.
Some therapies that are suitable to treat patients with
reversible conditions that are facing difficulties in deal-
ing with respiratory secretion, might not be suitable in
patients in palliative care. Suctioning is one such ther-
apy indicated to remove respiratory secretion from
patient’s airways, however, it is uncomfortable and asso-
ciated with complications, such as pain, uncontrollable
coughing, infection, atelectasis, hypoxemia, haemoptysis
and airway injuries [8]. In addition, palliative care guide-
lines suggest that the indication of suctioning procedure
should be done with caution, since it is a painful
procedure [9, 10].
Other pharmacological and non-pharmacological inter-
ventions have been clinically used to control respiratory
secretion and examples are mucolitics [11], antibiotics [3]
and respiratory physiotherapy [1, 12]. Systematic reviews
[11, 13] have shown that mucolitics and respiratory
physiotherapy have been successfully used in the manage-
ment of this symptom in patients with COPD, but not
specifically in the end stages.
However, there is no clear evidence on whether the
available interventions would be effective and suitable
for patients receiving palliative care, since patients facing
life-threatening diseases have specific treatment goals,
which are not always verified in studies with patients
with less severity.
Research question
What are the benefits of pharmacological and/or non-
pharmacological interventions in adult palliative care
patients that are facing problems in dealing with respira-
tory secretion?
Objective
The objective of this study was to identify which inter-
ventions are in use to control respiratory secretion in
patients with chronic disease with a poor prognosis and
verify their effects on outcomes relevant for palliative
care.
Methods
Search strategy and data extraction
The literature search was conducted in September 23th
of 2014, and updated in April 6th of 2016. The review
process involved:
1) A literature search was performed to retrieve jour-
nal articles and grey literature using the search strategy
(Additional file 1). Thereafter, the results were
imported to the reference software ENDNOTE X7®
(Thomson Reuters, New York, NY) (JB) 2).2) An initial
selection based on titles was performed by two inde-
pendent reviewers (JFA and JB) and possible disagree-
ments were resolved by a third reviewer (VAPDL).
Studies were excluded when they were duplicates or
clearly did not meet the inclusion criteria (Table 1) 3)
The abstracts of these studies were read and retained
where the content was relevant to the topic under con-
sideration (JFA and JB) with disagreements resolved by
a third reviewer (VAPDL) 4) The full papers were read
by two independent reviewers (JFA and EA) to verify
the inclusion criteria 5) A citation track and a reference
search of included studies was performed (JB) 6) Data
extraction was performed by two independent re-
viewers (JFA and EA) 7) The assessment of the meth-
odological quality of the studies was done by two
independent reviewers (JFA and VAPDL) using the PE-
Dro scale, a 11-item scale, which ten are included in
Table 1 Inclusion criteria
Inclusion Exclusion
Was the population studied with the severity of the chronic disease
identifiable and with one of the National Hospice Organization Criteria? [15]
Did the study involve a population with disease severity that is not
identifiable, or without any of the National Hospice Organization Criteria? [15]
Were the interventions performed to treat cough ineffectiveness,
respiratory hypersecretion or its consequences (relative distress)?
Were the interventions focused in treating other symptoms?
Was the study composed in its majority of adults? Did the study involve animals?
Was it a randomized clinical trial, observational study or a qualitative
study?
Was the study about death rattle?
Arcuri et al. BMC Palliative Care  (2016) 15:74 Page 2 of 11
the total score, in which higher scores represent better
methodological quality [14, 15]. Lastly, the evidence was
summarized using the Oxford Centre for Evidence-based
Medicine (OCEBM) levels of evidence 2011, this score
considered the level of evidence as (1) systematic reviews
of randomized controlled trials; (2) Randomized con-
trolled trials or observational studies with dramatic effect;
(3) Non-randomized trials/follow-up studies; (4) case
series, case-control studies or historically controlled stud-
ies and (5) Mechanism-based reasoning [16]. The level is
recorded in brackets against the studies.
Ethics approval was not requested since this study did
not involve humans, human data or animals.
Electronic search
The following databases were searched: AMED, British
Nursing Index, CINAHL, EMBASE, LILACS (for South
American publications), PEDro, MedLine, Web of
Science. The search carried out in MedLine is set out in
the table in the Additional file 1 and was adapted for use
in other databases.
Grey literature
Searches were carried out in clinical trials registers,
including the Cochrane Airways Group Specialised
Register of trials, thesis and dissertations databases,
NICE Evidence, GoogleScholar (JB). The studies re-
trieved were evaluated by two different reviewers (JFA
and NP) and any disagreement was resolved by a third
reviewer (VAPDL).
Outcomes
The primary outcomes of the review were subjective im-
pression on effectiveness of the intervention and com-
fort during therapy. Moreover, all outcomes used to
assess the therapies in the studies were included. The
outcomes were presented as mean ± standard deviation
or median (interquartile range 25–75 %). Based in their
opinion, authors classified the outcomes as critically
relevant, relevant or less relevant for clinical decision in
palliative care.
Results
The search was conducted in September 2014 and up-
dated in April 2016. 5413 papers were identified by the
search which resulted in 28 studies included in the re-
view, a study flowchart is on Fig. 1. These included six
randomized controlled trials [17–22] (Table 2), ten
cross-over trials [23–32] (Table 3), 11 observational
studies [33–43] and one qualitative study [44]. Associ-
ated conditions were multiple sclerosis [18, 21, 36],
neuromuscular disorders [19, 22–29, 31, 33–36, 38–44],
spinal cord injury [17, 30, 35, 37], COPD [20, 24] and
cystic fibrosis [32]. Interventions were mechanical
insufflation-exsufflation (MIE) [17, 22–29, 33–44],
manually assisted cough (MAC) [23, 25, 28, 29, 31], ex-
piratory muscle training (EMT) [18, 21], percussive venti-
lation [31], positive expiratory pressure (PEP) masks
associated [32] or not [20] to hypertonic saline nebulisa-
tion, abdominal muscles electrical stimulation [30] and
vibratory vest [19] (Table 4). Other interventions were
mentioned in the studies which were represented as usual
care but, since they were used alongside other interven-
tions, they lacked results for evidence summarization.
The randomized controlled trials and cross-over trials
had their methodological quality assessed by PEDro
Scale. The highest score (6 points) was achieved by
Chaisson et al randomized controlled trial, while the
lowest score (1 point) was achieved by Pillastrini et al.
[17] Only one study [19] achieved more than a half of
the criteria. Five of the six randomized controlled trials
did not conceal the random allocation, none were
blinded, and one was analysed in intention to treat. Fur-
thermore, only 50 % of the cross-over trials were
randomized, none had a concealed allocation, and only
one was blinded to the assessors [27]. Although the sam-
ple size is not assessed by PEDro scale, three random-
ized controlled trials do not present power calculation
[17, 19, 21]. The scores in PEDro scale are in Tables 2
and 3, and a detailed table is available in the Additional
file 1 Table S2 and Table S3).
Therapies to promote expectoration
Three therapies were found to help promoting expector-
ation (Table 4): MAC, tracheotomy (to facilitate suctioning
procedures) and MIE. MAC and tracheotomy are usual
procedures in patients with cough inefficiency. However,
MIE equipment is not usual in general hospitals, but is
relatively common in neuromuscular disease care centres.
MAC is a technique which increases peak cough flow
by manual thrust in the abdominal wall conducted by a
therapist or carer that can be optimized using some sort
of inspiratory aid, such as a resuscitation bag or mech-
anical ventilation [23]. It is a simple and relatively cost-
free intervention and should be the first line therapy in
cough inefficiency. Nevertheless, patients must have a
minimum level of cooperation; otherwise they would not
cough with the manual thrust [45] and in very severe
patients, it might cause fatigue. Moreover, abdominal
thrust may cause pain in some cancer patients.
MAC (Tables 2 and 3) was considered more comfort-
able than other techniques (level 3) [23] and led to an
increase in maximum expiratory pressure (PEMax) (level
3) [30] and peak cough flow (PCF) (level 2) [23, 25, 29]
and in two studies, the increase was high enough to
achieve a level of PCF (>270 L/min) considered to be ef-
fective [23, 29]. In addition, effectiveness was confirmed
by the patient’s subjective impression (level 3) [23, 29].
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However, one study presented contradictory results
[28] for PCF, comfort and effectiveness. This study used
a non-invasive mechanical ventilator for inspiratory as-
sistance and pressure was adjusted according to patient
comfort, while the studies with better outcomes used
the highest tolerable pressure or 40cmH2O [29] or air
stacking using a resuscitation bag [23, 25]. This contra-
diction suggests that the inspiratory aid should always
be the maximum tolerated or 40cmH2O. This finding is
corroborated by Senent and colleagues [23] who tested
both inspiratory aid of 30cmH2O and resuscitation bag
and found that the former was not as effective as the
latter.
Another intervention was tracheotomy, which is a
common procedure and associated with mechanical ven-
tilation which can increase survival (level 2) in patients
with cough insufficiency (amyotrophic lateral sclerosis
and Duchenne dystrophy) [39, 40], since it facilitates and
makes suctioning and ventilatory assistance more toler-
able. However, a surgical procedure is not usually the
choice in patients in palliative care, unless there is no
other non-invasive alternative. Moreover, tracheotomy
might impair speaking resulting in lower social inter-
action and swallowing (the tube weight decreases the
movements of the trachea, which changes the dynamics
of swallowing), which might not be compensated by the
gain in survival time.
The therapy with the most included studies was MIE
(Tables 2 and 3), where a patient receives a positive pres-
sure, by a mask or tracheotomy, to inflate the lungs,
followed by a negative pressure to promote expectoration.
Twenty one studies assessed MIE (two randomized con-
trolled trial, one qualitative study, seven cross-over trials
and 11 observational studies). A cross-over trial verified
Fig. 1 PRISMA Flowchart
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the effect of this therapy in COPD and neuromuscular
diseases [24]; one verified its effects in a group of patients
with respiratory failure with different illnesses [35], all the
other studies included patients with neurological [17, 37],
neuromuscular [22, 23, 26, 27, 29, 33, 34, 36, 38–44], or
both diseases [25, 28].
MIE is a promising therapy to promote expectoration in
palliative care. Firstly, it is more comfortable than suction-
ing (level 3), but this was only studied in tracheotomised
patients [26] and comfort might be even better in com-
parison with nasotracheal suctioning with MIE by a mask
which future studies need to confirm. In addition, the use
of MIE associated with non-invasive ventilation may
prevent, delay or allow the removal tracheotomy in
patients with NMD (level 2) [33, 35, 43], decrease respira-
tory complications [42] and hospitalizations [36]. A study
[22] verified no changes in hospitalization, antibiotics
days, pulmonary moridities using MIE when compared to
cough assisted by breathing stacking technique. However,
this study had more severe patients included in MIE
group when compared to breath stacking group, which
may have influenced the results.
Secondly, according to patients’ subjective assess-
ments, MIE was more effective than suctioning (level 3)
[26] and, when associated to MAC, MIE was more
effective than MAC alone [23, 29]. In a randomized con-
trolled trial, Pillastrini and colleagues [17] verified an
increase in PCF which corroborates the effectiveness
findings. Moreover, increase in PCF values was verified
by other studies and a systematic review, and it in-
creased above 270 L/min (level 1) [23, 25, 29, 46]. Fur-
thermore, MIE improves oxygenation in COPD and
NMD patients [24].
Thirdly, MIE is a therapy that can be conducted by fam-
ily carers and it brought the feeling that they were able to
do something for the patient (level 4) [44]. It may be one
of the factors why MIE along with other non-invasive ven-
tilation approaches reduced the number of patients with
Duchenne Dystrophy that were living in a rehabilitation
hospital [42]. Nevertheless, MIE is contra-indicated when
Table 2 Randomized clinical trials
Population\PEDro Scale Groups Intervention Outcomes
Pillastrini et al (2006) [17]
Upper Spinal Cord Injury
1
Control (n = 4) Chest Physiotherapy No improvement: FVC; FEV1; PCF; FEV1/FVC; PaO2; PaCO2; Ph; SaO2.
Experimental
(n = 5)
Chest Physiotherapy +MIE Improvement: FVCa (Before 0.37 ± 0.23 ml /After 0.46 ± 0.21;↑24 %); FEV1
a
(Before 0.21 ± 0.15 ml /After 0.28 ± 0.14; ↑33 %); PCFa (Before 0.24 ± 0.19 L/s
/After 0.31 ± 0.19 L/s;↑29 %).
No improvement: FEV1/FVC; PaO2; PaCO2; Ph; SaO2.
Gosselink et al (2000) [18]
Multiple Sclerosis
5
Control (n = 9) Non-supervised breathing
exercises
No Improvement: PIMax; Pulmonary Index, FVC; PEMax.
Training (n = 9) Expiratory muscle training
(Threshold)
Improvement : PIMaxa (↑39 ± 41cmH2O); Pulmonary Index
b (↓ 2 ± 1pts).
No Improvement: FVC; PEMax.
Chaisson et al (2006) [19]
ALS
6





cough + Vibratory vest
No improvement: Respiratory complications; Rate of decline in FVC;
Survival days.




Control (n = 22) SHAM therapy with
low PEP mask
No improvement: FEV1; FVC; PaO2; PaCO2; dyspnoea during activities;




Therapy with PEP mask No Improvement: FEV1; FVC; PaO2; dyspnoea walking on ground level;
sputum; exacerbations; bedridden days; hospitalizations and days with
antibiotics.
Worsening: Coughb [↓11 (−69–75)mm]; PaCO2 [↑0.05(−69–75)kPa]
b;
dyspnoea walking on staircaseb [↓1 (−69–53)mm].
Smeltzer et al (1996) [21]
Multiple Sclerosis
4
Control (n = 5) SHAM therapy with
Threshold





Improvement: PEMaxb (19,4 ± 9.9cmH2O; ↑19 %).
No improvement: PIMax.





Breath Stacking Therapy No improvement: Hospital Admissions, number of antibiotics days,
pulmonary morbidities, Survival, quality of life.
MIE (n = 19) MIE No Improvement: Hospital Admissions, number of antibiotics days, Hospital
Admissions, number of antibiotics days, pulmonary morbidities, Survival,
quality of life.
Values presented as mean ± standard deviation or median (interquartile range). apre-post intra-group comparison; bstatistical difference between groups; FVC
forced vital capacity, FEV1 forced expiratory volume in the first second, PCF peak cough flow, PaO2 Arterial pressure of oxygen, PaCO2 Arterial pressure of carbon
dioxide, SaO2 Arterial Oxygen Saturation, MIE Mechanical Insufflation-Exsufflation, PIMax Maximum inspiratory pressure, PEMax Maximum expiratory pressure,
COPD Chronic obstructive pulmonary disease, PEP Positive expiratory pressure, ALS Amyotrophic lateral sclerosis, NMD Neuromuscular Disease
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Table 3 Cross-over trials
Population/PEDro Scale Interventions Outcomes
Senent et al (2011) [23]
Neuromuscular






cough + abdominal thrust
No improvements
Abdominal thrust + Air
Stacking
Improvements: PCF:284(146–353)L/min, ↑238 % than baseline 84(35–118)L/min
(statistically higher than first two methods)
Abdominal thrust + usual patient’s
bi-level ventilator
Improvements: PCF:212(99–595)L/min, ↑152 % than baseline (statistically higher
than first two methods)/Comfort (VAS): 8(7–8)pts,↑60 % than baseline 5(4–7)pts
(statistically higher than all other methods).
Abdominal thrust + IPAP
of +30cmH2O
Improvements: PCF: 233(100–389)L/min, ↑177 % than baseline (statistically higher
than first two methods).
MIE (40cmH2O) Improvements: PCF: 488(243–605)L/min (↑480 %) than baseline/Effectiveness
(VAS): 8(6–8)pts ↑100 % than baseline 4(2–7)pts (statistically higher than all
other methods).
NMD (n = 7) ALS (n = 13) COPD (n = 9)
Winck et al (2004) [24]
Neuromuscular Disease
and COPD (n = 29)
3
MIE (15cmH2O) No Improvements No Improvements No Improvements
MIE (30cmH2O) No Improvements No Improvements No Improvements
MIE (40cmH2O) Improvements: PCF:
220(190–300)L/min,
↑22 % than baseline 180
(150–275)L/min/SpO2:
94(92–96), than 98(97–98),
↑4 %/Dyspnoea (BORG) 0.75
(0–2.3)pts, ↓62 % than baseline
2(0.4–3.3)pts.
Improvements:PCF:200
(170–352)L/min ↑17 % than
baseline 170(128–300)L/min/













Air Stacking Improvements: PCF: 3.37 ± 1.07 L/s, ↑86 % than baseline 1.81 ± 1.03 L/s
Manually Assisted Cough Improvements: PCF: 4.27 ± 1.29 L/s, ↑135 % than baseline
MIE (Individualized pressure) Improvements PCF: 7.47 ± 1.02 L/s, ↑312 % than baseline (higher than all other
methods)/FVC: 0.54 ± 0.39 L, ↑10 % than baseline 0.49 ± 0.37 L/FEF25-75 %:
0.91 ± 0.69 L/s, ↑13 % than baseline 0.80 ± 0.59 L/s
Sancho et al (2003) [26]
ALS (n = 6)
5
Tracheal Suctioning Improvements: WB: 0.95 ± 0.23 J/L, ↓7 % than baseline 1.03 ± 0.25 J/L
Worsening: All patients referred as less comfortable and effective than MIE
MIE (40cmH2O) Improvements: SpO2:,↑3 % than baseline 93.5 ± 2.25 %/Peak Inspiratory Pressure:
15.33 ± 4.13cmH2O, ↓17 % than baseline 18.5 ± 4.23cmH2O/Mean Airway Pressure:
3.83 ± 1.72cmH2O, ↓8 % than baseline 4.67 ± 1.37cmH2O/WB: 0.87 ± 0.26, ↓15 %
than baseline
Population/PEDro Scale Interventions Outcomes


















Exsufflation Assisted Cough Improvements: PCF ↑a
MIE Improvements: PCF ↑a




MIE (highest tolerable pressure) Improvements: PCF ↑ a than baseline; Effective Cough Time ↑a compared to baseline
MAC + IPAP Improvements: Effectiveness: 8.3(7.2–9)pts, ↑29.6 % than MIE 6.4(4.8–8.2)pts; PCF ↑a;
Effective Cough Time ↑ a (all compared to MIE)
MAC +MIE (highest tolerable
pressure)
Improvements: Effectiveness: 8.5(6.2–9)pts, ↑32.8 % higher than MIE; PCF ↑a; Effective
Cough Time↑a (all compared to MIE)
Linder (1993) [30] Cough with FES Improvements: PEMax: 60 ± 22.8cmH2O, ↑119,7 % than baseline 27.3 ± 6.4cmH2O
MAC Improvements: PEMax: 83 ± 18.7cmH2O, ↑ 38.3 % than Cough with FES
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patients present increased risk of pneumothorax, which
might happen in patients with some cancers, such as sar-
coma, lung carcinoma, germ cell tumor or lymphoma [47].
Therapies to facilitate mucus clerance
Before providing aid to promote expectoration, a therap-
ist should perform some interventions to help the mucus
collection from peripheral areas of the lung, to central
airways, such as the trachea, where a cough or suction-
ing are able to remove the secretions from the airways.
Although chest physiotherapy is the most commonly
used therapy, it was only present in studies as a control
therapy; there were no studies that compared it to no-
treatment in patients in palliative care. Moreover, what
was considered as chest physiotherapy was not the same
in each study, and may have included manual vibration,
postural drainage, manual or mechanical hypersinsufla-
tion, chest compressions, PEP masks and suctioning.
Nevertheless, two studies [17, 27] assessed the pre and
post effects of chest physiotherapy (as a control therapy).
They verified that chest physiotherapy was as effective as
chest physiotherapy plus MIE, however the latter re-
quired more therapy time [27]. Moreover, chest physio-
therapy improved arterial pressure of oxygen in 32 % of
participants, but the result was not statistically signifi-
cant, probably due to the small sample size (n = 5) [17].
In addition, some evidence was found regarding other
interventions with the same goal, such as PEP [20, 32],
vibratory vest [19], percussive ventilation [31]..
The therapy using PEP masks (Tables 2 and 3) im-
proves mucus collection as it maintains the opening of
peripheral airways during a forced expiration longer than
without the device, which may influence the mucus
clearance by increasing the period of expiratory flow.
However, only one study was found in very severe
COPD patients [20] and another in cystic fibrosis with
very severe obstruction [32], which fitted palliative care
criteria. In patients with COPD, this therapy may in-
crease the discomfort caused by cough and dyspnoea
while walking up a staircase (level 2) [20]. Nevertheless,
in patients with cystic fibrosis, PEP masks associated
with saline jet nebulizers improved the chest tightness
subjective feeling when compared to only saline jet neb-
ulisation (level 3) [32]. However, in the authors’ opinion,
since chest tightness is a less relevant outcome (an ad-
verse effect of hypertonic saline nebulisation), the use of
PEP mask are not recommended in both diseases until
more evidence is found.
The therapy with oscillations or vibrations is based on
the effects on increasing the mucociliary function, which
mobilizes the secretions from peripheral airways and
alter the mucus rheology [19]. Two ways to provide
oscillations were found in the review, which were high
frequency chest wall oscillations, commonly known as a
vibratory vest (Table 2) and percussive ventilation
(Table 3). The first method is a vest that inflates until
the thorax is gently pressed. When the device is turned
on, it inflates and deflates in a determined frequency (5-
20Hz) that produces a vibration in the chest wall that is
transferred to the airways and mucus. This method was
assessed in amyotrophic lateral sclerosis (ALS) patients
and failed to improve survival, rate of forced vital capacity
(FVC) loss and the number of respiratory complications
(level 3) [19]. However, some problems in the study, such
as the difference in age between groups and the small
sample (n = 4 in control group and n = 5 in experimental
group), are issues that prevent a better judgment in the
use of the therapy. The percussive ventilation presented
more promising results, resulting in a higher amount of
secretion suctioned after the procedure, compared to
usual care (level 3) [31]. Percussive ventilation is a therapy
in which air pressure is provided by a device by a mask,
endotracheal tube or tracheotomy and this pressure oscil-
lates generating a vibration directly in the airways.





Toussaint et al (2003) [31]
Duchenne dystrophy
patients (n = 8)
4
Cough assistance techniques No improvements
Percussive Ventilation + cough
assistance techniques
Improvements: Removed secretion: 6.53. ± 4.77 g,↑42.8 % than Cough assisted
techniques 4.57 ± 3.5 g; (Only in a sub-group of five hypersecretive patients)
O’Connell, et al (2011) [32]







Improvements: Subjective report of chest tightness 1.7pts, ↓68 % than without
PEP mask 5.3pts
Values presented as mean ± standard deviation or median (interquartile range). Insufflation-Exsufflation; MAC Manually assisted cough, NMD Neuromuscular
Disease, ALS Amyotrophic lateral sclerosis, COPD Chronic obstructive pulmonary disease, SpO2 Peripheral oxygen saturation, FVC Forced vital capacity, FEF25–75 %
Mean forced expiratory flow at 25–75 % expiratory period, WB Work of breath, FES Functional electrical stimulation, PEMax Maximum expiratory pressure, PEP Positive
expiratory pressure. aResults presented graphically in the original paper
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Therapies to improve cough efectiveness
Some therapies are intended to help the individual to re-
gain cough function, when this reaction is lost for some
reason. Usually, it requires activating the expiratory
muscles by an external stimulus [30] or increasing the
expiratory muscle strength [18, 21]. When patients still
have muscle mass, but are not able to activate it due to
neurological impairment, such as spinal cord injury,
functional electrical stimulation (FES) (Table 3) may
help improve cough effectiveness by activating the
abdominal muscles that were not functional [30]. One
cross-over trial, with a small sample size, verified the use
of FES in spinal cord injury and verified an increase in
PEMax compared to control (level 3) [30]. However,
more meaningful outcomes should be studied before
suggesting the use of this therapy in palliative care
patients, such as subjective impression of effectiveness,
comfort during therapy, fatigue caused by the therapy
and PCF.
Expiratory muscle training (Table 2) is largely used in re-
spiratory physiotherapy [48] but only two studies [18, 21]
were found in patients with very severe stages of the
Table 4 Evidence summary
Intervention Disease Critically relevant for clinical decision


















COPD — — — — ↓ 3 — — — — — —
SCI — — — — — — ↔ 3 — ↔ 3 — —
NMD ↑ 1a ↑ 3 ↔ 2 ↑2 ↓ 3 ↔ 2 ↕ 2 ↓ 3 ↕2 ↑2 —
EMT MS — ↑ 2 — — — — — — — — —
MAC NMD ↑3 ↑ 2 — — — — — — — — —
PEP Mask COPD — — — — — ↔ 2 — — ↔ 2 — ↑ 2
CF — — — — — — — — — — —
FES SCI — — — — — — — — — — —
Percussive
ventilation
NMD — — — — — — — — — — —
Vibratory
vest
NMD — — — ↔ 3 — — — — ↔ 3 — —
Tracheotomy NMD — — — ↑2 — — — — — — —
Table 4 Evidence summary (Continued)
Intervention Relevant for Clinical Decision Less Relevant for Clinical Decision
Oxygenation Dyspnoea during
exercise
PCF FEV1 FVC Secretion
Amount




↑ 3 — ↔ 3 — — — — — — — —
↔ 3 — ↑ 3 ↑ 3 ↑ 3 — ↔ 3 — — — —
↑ 3 — ↑ 1a — ↑3 — — — — — —
EMT — — — — — — — — — ↕ 2 ↕ 2
MAC — — ↑ 2 — — — — — — — ↑3
PEP Mask ↔ 2 ↕ 2 — ↔ 2 ↔ 2 ↔ 2 ↑ 2 — — — —
— — — — — — — ↓3 — — —
FES — — — — — — — — — — ↑3
Percussive
ventilation
— — — — — ↑ 2 — — ↔ 2 — —
Vibratory
vest
— — — — ↔ 3 — — — — — —
Tracheotomy — — — — — — — — — — —
OCEBM levels of evidence: 1- Systematic reviews / 2- Randomized controlled trials or observational studies with dramatic effect / 3: Non-randomized trials/follow-up studies
PCF Peak cough flow, FEV1 Forced expiratory volume in the first second, FVC Forced vital capacity, PaCO2 Arterial pressure of carbon dioxide, PIMax Maximum
inspiratory pressure, PEMax Maximum expiratory pressure, COPD Chronic obstructive pulmonary disease, SCI Spinal cord injury, NMD Neuromuscular disease,
EMT Expiratory muscle training, MS Multiple sclerosis, MAC Manually assisted cough, PEP Positive expiratory pressure, CF Cystic fibrosis, FES Functional electrical
stimulation; ↑: increase; ↓: decrease; ↕: conflicting results; ↔: No change. aConsidered the systematic review from Morrow and colleagues [46]
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disease. Both studies verified expiratory muscle training
on cough effectiveness in patients with multiple sclerosis
with respiratory muscle impairment. The results of the
studies regarding this training were conflicting. One study
presented an increase in PEMax and no significant change
in maximum inspiratory pressure (PIMax) [21], while the
other study verified improvement in PIMax, subjective
cough effectiveness assessment and FVC and no change
in PEMax [18]. Nevertheless, expiratory muscle training
might be a suitable therapy only in very specific situations
in palliative care, since an adequate nutritional balance
and a long-term adherence to the therapy are essential to
a clinically significant strength improvement [49], which
are not usually possible in this population.
Discussion
This paper systematically reviewed literature on interven-
tions used to manage the presence of respiratory secretion.
Nevertheless, there was limited evidence for most of the
interventions and most were restricted to neurological and
neuromuscular patients.
The low number of randomized controlled trials is simi-
lar to other reviews of symptom control in palliative care.
Moreover, some interventions (such as tracheotomy) may
be considered essential or usual care to patients despite
the absence of evidence and therefore not providing this
therapy to a group of patients in randomized controlled
trial would be considered unethical.
The included randomized controlled trials and cross-
over trials had a low overall methodological quality. Al-
though some methodological quality criteria are usually
not achievable by non-pharmacological interventions,
such as blinded therapists and patients, some criteria are
possible to be met, which affects the trust in the results.
Although diseases in advanced stages, such as dementia
and cancer, do often result in the occurrence of discomfort
due to respiratory secretion, no studies regarding these dis-
eases were found, probably due to the reduced number of
studies focusing patients’ comfort and symptom control in
comparison to studies with therapies to control the ad-
vance of these diseases. There were only a limited number
of studies on diseases where this condition is usually found
[4], such as respiratory diseases. Neuromuscular diseases
[45], such as Duchenne muscular dystrophy and amyo-
trophic lateral sclerosis, were more frequently studied.
Most therapies found in this review could be applied
in palliative care situations, however more studies must
be conducted to strengthen the evidence and broaden
the populations that could be treated, especially in can-
cer. In addition, no studies were found which assessed
drug therapy to relieve this symptom, which suggests
that the use of anti-muscarinic drugs and mucolytics are
based in studies that included patients with lower sever-
ity of the disease, or patients with death rattle.
More research is required for a better understanding of
the efficacy of pharmacological and non-pharmacological
therapies used in respiratory secretion management in
patients in palliative care. The studies should be
conducted with patients who may die in the following
year, but are not so close to dying that respiratory secre-
tion is considered to be treated only due to the sound it
produces.
Additionally, none of the studies presented as the main
outcome a patient-reported outcome measure (PROM),
such as comfort and subjective effectiveness impression.
These PROMs are critically relevant in authors’ opinion,
since they capture the preferences and impressions of
the patient, which is essential when assessing a palliative
intervention [50]. However, these PROMs were assessed
as secondary outcomes to MAC and MIE interventions,
and for both PROMs, they were considered acceptable
by patients. Interventions to improve mucus clearance
and to increase cough effectiveness were not assessed re-
garding subjective impression of effectiveness or comfort.
Therapies that most probably suited palliative care
patients are MAC and MIE as they both promote expec-
toration, chest physiotherapy and percussive ventilation
applied by non-invasive methods to improve mucus clear-
ance. Therapies that simply improve voluntary cough
effectiveness are less likely to be used in this context. Drug
therapy, such as mucolytics and anti-muscarinic agents
should also be studied to verify their short and long term
effects. In addition studies that assess the subjective
experience of treatment by patients are required.
Study limitations
Understandably this review has some limitations. Ini-
tially, the review was not prospectively registered. More-
over, a meta analysis was not done due to the large
number of outcomes and therapies and the difference in
methods among the studies would have affected this
meta analysis; however, a broad overview of therapies
which could be used in palliative care were identified,
which can guide future steps in the research field. More-
over, the identification of studies that included patients
who could be in a palliative care treatment were done
using severity indices [51], such as forced expiratory
volume in the first second in respiratory diseases and
respiratory muscle impairment in neuromuscular and
neurological diseases. Nevertheless this would be diffi-
cult to do, as few of the studies defined the population
as palliative. Instead we included studies with patients
suffering with an advanced disease akin to a palliative
care population.
Conclusion
Therapies, such as MAC, MIE and percussive ventilation,
which aim to deal with respiratory secretion, can be used
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in palliative care of specific diseases. Nevertheless, the evi-
dence still needs to improve in order to identify which
alternative is the best.
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